In our recently published work, we have utilized data from two large retrospective datasets: a German claims dataset and the UK General Practitioner (GP)-based Clinical Practice Research Datalink (CPRD) dataset (2010–2012). The study included 1,905 and 1,627 type 2 diabetes mellitus (T2DM) patients receiving glucagon-like peptide-1 (GLP-1) receptor agonists from the UK and Germany, respectively.

The aim was to assess the level of non-persistence (NP) and non-adherence (NA) to therapy with GLP-1 receptor agonists in T2DM patients. This study is unique from most other adherence studies in analyzing non-persistence and non-adherence separately.

Percentage of NP patients after 12 months was 29.5% in the UK and 36.4% in the German sample. In both countries, a twice-a-day treatment was associated with a higher probability to discontinue a treatment with GLP-1 receptor agonists earlier than a once-a-day treatment. The percentages of patients considered NA were 20.2%/20.0%/20.5% (all/once-a-day/twice-a-day) for the UK sample, and 19.9%/19.2%/ 21.8% (all/once-a-day/twice-a-day) for the German sample. In summary, NP and NA to treatment with GLP-1 receptor agonists in both UK and Germany appear to be similar. Persistence to OD treatment is higher than to BID  treatment in both the UK and Germany.

If you are interested in more information, please do not hesitate and CONTACT US!